IOncology

Editor’s Note: China, Japan, South Korea and other East Asian countries share a high prevalence of hepatobiliary and pancreatic tumors, yet current treatment options still fall short of clinical needs.…

China, Japan, and other Asian countries represent the regions with the highest global incidence of gastric cancer. In China, most patients are still diagnosed at advanced stages, losing the opportunity for curative surgery. Effective systemic therapies are therefore critical to improving survival. In recent years, innovative therapies—particularly antibody–drug conjugates (ADCs)—have shown promising results. Among them, the HER2-targeted ADC trastuzumab deruxtecan (T-DXd) has achieved success in key clinical studies such as DESTINY-Gastric04, and is poised to reshape treatment paradigms starting from later-line settings. Asian investigators have played an important role in these practice-changing studies.

The 2025 China Conference on Holistic Integrative Oncology (CCHIO), jointly hosted by the Chinese Anti-Cancer Association (CACA), the Organizing Committee of the Tengchong Scientists Forum, the World Association of Integrative Oncology (WAIO), and the China Academy of Integrative Medicine Development Strategy, was held in Kunming, Yunnan from November 6–9, 2025. On November 7, the CACA–UICC Special Session, co-organized by CACA and the Union for International Cancer Control (UICC), concluded successfully. The session brought together experts and scholars from China and abroad to discuss comprehensive cancer management, global challenges and opportunities, and collaborative strategies for advancing global cancer control. 

Editor’s Note: The 2025 China Conference on Holistic and Integrative Oncology (CCHIO) was held in Kunming from November 6–9, 2025. The meeting was hosted by the China Anti-Cancer Association (CACA)…

Editor’s Note: At the 2025 ESMO Annual Congress, the breast cancer field once again witnessed multiple breakthroughs—ranging from the DESTINY-Breast09 study, which redefined first-line therapy for advanced HER2-positive breast cancer,…

Editor’s Note: The 2025 Second Forum on Innovative Anticancer Drug Clinical Research and the 9th East China Breast Cancer Salon, hosted by the Beijing Sci-Tech Medical Development Foundation and organized…

Fostering Cell Therapy Innovation in Latin America: Insights from Prof. Alejandro Madrigal Fernandez, OBEIn a recent interview, Alejandro Madrigal Fernandez, OBE FMedSci MD PhD FRCP FRCPath DSc HonDSci Professor of Haematology,…

Professor Arnon Nagler from the Sheba Medical Center in Tel Aviv, Israel, discussed the paradigm shift of applying CAR-T cell therapy, a cornerstone of hematologic oncology, to the complex world…

During the 2025 ESMO Congress, the first and only ESMO-authorized “ESMO China Focus” Uro-Oncology Session was successfully held on October 19 in Berlin. The forum highlighted major advances in urothelial carcinoma and prostate cancer, bringing together Chinese and international experts for in-depth academic discussions and intellectual exchange. Experts agreed that data from landmark studies such as EV-302 and EV-103 firmly establish enfortumab vedotin (EV)–based combination therapy as the new first-line standard of care for locally advanced or metastatic urothelial carcinoma (La/mUC). In addition, androgen-receptor pathway inhibitors (ARPI), represented by enzalutamide—which remains the only ARPI with 8-year overall-survival follow-up—continue to redefine long-term survival expectations for patients with prostate cancer, marking a new era for uro-oncology.